Literature DB >> 3034787

Cell lines of human germinal cancer.

J Casper, H J Schmoll, U Schnaidt, C Fonatsch.   

Abstract

Three new established human germ cell tumour lines, H 12.1, H 12.5 and H 12.7, are described. Cytogenetic and growth characteristics, morphology, histology, and tumour marker and steroid hormone production in vitro and/or in vivo revealed properties commonly found in other germ cell tumour lines and in patients with these tumours. In vitro oestrone and oestradiol were produced by the H 12 lines and four other lines (833 KE, 1156 Q, 1428 A and 2102 EP) under high and low density (differentiation inducing) conditions. AFP was produced by one line and beta-hCG by six of seven lines under low density conditions. The pattern of oestrogen production suggests that these hormones could be useful in AFP and beta-hCG negative patients. Differentiated elements of somatic and extraembryonic character, observed in tumours of H 12.1 and H 12.7, underline the value of these lines in the study of differentiation and other germ cell tumour related questions.

Entities:  

Mesh:

Year:  1987        PMID: 3034787     DOI: 10.1111/j.1365-2605.1987.tb00171.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  17 in total

1.  Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts.

Authors:  T A Dunn; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines.

Authors:  T A Dunn; H J Schmoll; V Grünwald; C Bokemeyer; J Casper
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

3.  Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity.

Authors:  Thomas Mueller; Lutz Peter Mueller; Hans-Juergen Holzhausen; Ralf Witthuhn; Peter Albers; Hans-Joachim Schmoll
Journal:  Histochem Cell Biol       Date:  2010-06-08       Impact factor: 4.304

4.  Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines.

Authors:  W Verbeek; C Bokemeyer; H Falk; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours.

Authors:  C Bokemeyer; M A Kuczyk; T Dunn; J Serth; K Hartmann; J Jonasson; T Pietsch; U Jonas; H J Schmoll
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 6.  Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.

Authors:  Silvia Schmidtova; Katarina Kalavska; Lucia Kucerova
Journal:  Curr Oncol Rep       Date:  2018-09-26       Impact factor: 5.075

7.  Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.

Authors:  C Bokemeyer; L M Fels; T Dunn; W Voigt; J Gaedeke; H J Schmoll; H Stolte; H Lentzen
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

8.  Glycolipids of human primary testicular germ cell tumours.

Authors:  R A Olie; B Fenderson; K Daley; J W Oosterhuis; J Murphy; L H Looijenga
Journal:  Br J Cancer       Date:  1996-07       Impact factor: 7.640

9.  Monitoring of xenograft tumor growth and response to chemotherapy by non-invasive in vivo multispectral fluorescence imaging.

Authors:  Henrike Caysa; Stefan Hoffmann; Jana Luetzkendorf; Lutz Peter Mueller; Susanne Unverzagt; Karsten Mäder; Thomas Mueller
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

10.  The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.

Authors:  C Bokemeyer; H J Schmoll; E Ludwig; A Harstrick; T Dunn; J Casper
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.